A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease.

[1]  Jun Zhao,et al.  Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. , 2021, The Lancet. Oncology.

[2]  D. Maucort-Boulch,et al.  Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Berkowitz,et al.  Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. , 2020, Gynecologic oncology.

[4]  N. Sebire,et al.  When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. , 2019, Gynecologic oncology.

[5]  R. Berkowitz,et al.  Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  A. Akarca,et al.  Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia , 2017, The Lancet.

[7]  A. Schott,et al.  PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes , 2016, International Journal of Gynecologic Cancer.

[8]  R. Berkowitz,et al.  Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. , 2018, Gynecologic oncology.